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MyoD regulates skeletal muscle differentiation (SMD) and is essential for repair
of damaged tissue. The transcription factor nuclear factor kappa B (NF-kB) is
activated by the cytokine tumor necrosis factor (TNF), a mediator of skeletal
muscle wasting in cachexia. Here, the role of NF-kB in cytokine-induced muscle
degeneration was explored. In differentiating C2C12 myocytes, TNF-induced
activation of NF-kB inhibited SMD by suppressing MyoD mRNA at the post-
transcriptional level. In contrast, in differentiated myotubes, TNF plus inter-
feron-g (IFN-g) signaling was required for NF-kB–dependent down-regulation
of MyoD and dysfunction of skeletal myofibers. MyoD mRNA was also down-
regulated by TNF and IFN-g expression in mouse muscle in vivo. These data
elucidate a possible mechanism that may underlie the skeletal muscle decay in
cachexia.
The vertebrate skeletal muscle differentiation
(SMD) program is under the strict control of
the myogenic bHLH transcription factor fam-
ily (MyoD, Myf5, myogenin, and MRF4) and
of a second class of transcription factors
termed myocyte enhancer factor–2 (MEF2A
through MEF2D) (1, 2). MyoD and Myf5 are
expressed in proliferating undifferentiated
myoblasts and, upon growth factor withdraw-
al, are activated to initiate SMD that ultimate-
ly leads to the fusion of myoblasts into
multinucleated myotubes (1, 2). Although
mice lacking MyoD develop normally (3),
MyoD-deficient skeletal muscle is severely
impaired in its ability to regenerate after tis-
sue injury, which suggests a specific role for
MyoD in the replenishment of lost muscle
(4).
NF-kB is a transcription factor expressed
in a variety of cell types, including mature
muscle (5), and it inhibits SMD by regulat-
ing the expression of cyclin D1 (6 ). The
cytokine tumor necrosis factor (TNF) is a
potent activator of NF-kB, causing it to
translocate to the nucleus and bind to pro-
moters and enhancers of genes involved in
inflammatory and proliferative responses
(7–9). TNF is an important mediator of
skeletal muscle degeneration associated
with cachexia, a debilitating syndrome
characterized by extreme weight loss and
whole-body wasting (10–12). Cachexia is
frequently seen in patients afflicted with
chronic diseases such as cancer and ac-
quired immunodeficiency syndrome. It is
striking that about one-third of cancer mor-
talities result from cachexia rather than tu-
mor burden (13). Little is known about the
molecular etiology of cachexia, and hence
few targets have been identified for thera-
py. Here we investigate the potential role of
NF-kB as a downstream effector of TNF-
mediated skeletal muscle dysfunction.
TNF was recently shown to inhibit skeletal
myogenesis in vitro (6, 14). We therefore in-
vestigated the potential role of NF-kB in this
regulatory process. The addition of TNF to
mouse C2C12 myocytes completely blocked
their SMD program, as evidenced by the re-
duced expression of the differentiation markers
myogenin and the cyclin-dependent kinase in-
hibitor p21, and by the complete absence of the
late-stage differentiation marker myosin heavy
chain (MHC) (Fig. 1A). TNF also caused a
severe reduction in MyoD protein levels (Fig.
1B) but had no effect on the transcription fac-
tors Myf5 or MEF2D, which are also expressed
but are inactive in undifferentiated myoblasts.
Stable heterologous expression of MyoD re-
stored the ability of C2C12 cells to maintain
SMD (Fig. 1C) and form myotubes (15) in the
presence of TNF, indicating that TNF inhibits
myogenesis by down-regulating MyoD. The
rapid loss of MyoD protein was preceded by an
equally rapid loss of MyoD mRNA (Fig. 1D).
In addition, cells devoid of NF-kB activity
[through stable expression of the NF-kB inhib-
itor IkBa (IkBaSR)] retained MyoD mRNA in
the presence of TNF (Fig. 1D), indicating that
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20% fetal bovine se-
rum] to differentiation
medium [DM: DMEM-
H, 2% horse serum,
and insulin (5 mg/ml)]
and treated with or
without TNF (Pro-
mega) at 20 ng/ml for
a 72-hour period (to
sustain NF-kB activi-
ty, TNF was also add-
ed at 6, 12, and 24
hours after the initial
treatment). At indi-
cated times, whole-
cell extracts were pre-
pared and probed for SMD markers myogenin and the cyclin-dependent kinase inhibitor p21
(M-225 and C-19, Santa Cruz Biotechnology), MHC (MY-32, Sigma), or a-tubulin (Sigma). (B) TNF
regulation is specific to MyoD. Extracts from C2C12 cells in DM treated with or without TNF were
probed for MyoD, Myf5 (M-318 and C-20, respectively, Santa Cruz Biotechnology), and MEF2D
(Transduction Laboratories). (C) Overexpression of MyoD restores SMD in the presence of TNF.
C2C12 cells were infected with pBabepuro virus containing MyoD cDNA, and selected with
puromycin (1 mg). Clones were screened for their expression of MyoD and p21 (15). Vector control
cells and three independent clones—pBabeMyoD1, -4, and -7—were treated with TNF in DM, and
extracts were probed for p21 (after 48 hours) and MHC (after 72 hours). (D) TNF regulation of
MyoD is dependent on NF-kB activity. Vector control or cells lacking NF-kB activity (IkBaSR) were
differentiated and treated with TNF. At the indicated times, MyoD and GAPDH mRNA expression
was analyzed.
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NF-kB is a downstream TNF effector that reg-
ulates MyoD expression.
To examine which NF-kB subunits were
involved in the regulation of MyoD, reporter
assays were performed in mouse 10T1/2 fi-
broblasts. Coexpression of p50 and p65 sub-
units, or of the p65 subunit alone, strongly
blocked MyoD activity, and this effect was
reversed with equivalent expression of the
IkBaSR plasmid (16). Examination of
whole-cell lysates from these transfections
demonstrated that p65 alone was sufficient to
dramatically reduce MyoD protein levels
(Fig. 2A), and this inhibition was again lost
after the expression of IkBaSR. In addition,
similar to what was observed with TNF treat-
ment of C2C12 cells, overexpression of p65
reduced MyoD mRNA levels (Fig. 2B).
These results demonstrate that TNF regula-
tion of MyoD in C2C12 cells is dependent on
NF-kB activity and that the p65 subunit is
sufficient to induce the down-regulation of
MyoD mRNA.
These transfection results showed that p65
regulated MyoD transcripts produced from a
heterologous promoter. This suggested that
NF-kB was ultimately targeting the MyoD
mRNA itself for down-regulation. We there-
fore attempted to map the MyoD sequences
that rendered the mRNA susceptible to p65-
mediated down-regulation. Deletion analysis
revealed that nucleotides 539 through 914 in
the MyoD mRNA were required for this re-
sponse (Fig. 3A). Introduction of this MyoD
fragment into the coding region of the
GAPDH gene resulted in a p65-dependent
reduction in GAPDH mRNA levels (Fig. 3B),
confirming that p65 targets this MyoD se-
quence. We next examined whether NF-kB
inhibition of MyoD mRNA was direct or
indirect (that is, requiring NF-kB–dependent
transcription). MyoD mRNA decay rates, de-
termined in experiments in which transcrip-
tion was blocked with actinomycin D, were
similar whether C2C12 myoctyes were treat-
ed or not treated with TNF (16 ), which
suggests that regulation of MyoD is depen-
dent on an NF-kB–responsive gene. To test
the requirement for the transcription func-
tion of p65 in the regulation of MyoD, we
performed reporter assays in mouse 10T1/2
fibroblasts with deletion mutants lacking
regions of the p65 transactivation domain.
Deletion of the entire transactivation do-
main of p65 [Fp65(313)] restored MyoD
function (Fig. 3C). These data are consis-
tent with those in Fig. 2A, where the p50
subunit of NF-kB, which lacks a transacti-
vation domain, was also unable to inhibit
MyoD expression. Taken together, these
data indicate that MyoD mRNA is inhibited
at the posttranscriptional level in a manner
requiring NF-kB– dependent transcription.
TNF is an important mediator in the skel-
etal muscle degeneration associated with can-
cer-induced cachexia (10–12). Direct inhibi-
tion of NF-kB also blocks cachexia in an
animal model (17), suggesting a link between
NF-kB and TNF in this disease. Although
delivery of TNF is sufficient to induce weight
loss in animals, in vitro studies showing that
skeletal muscle explants incubated with TNF
do not undergo degeneration (18) support the
notion that at least one other factor is required
to induce muscle wasting. Consistent with
these findings, we found that in contrast to
the effect of TNF on differentiating myo-
blasts, differentiated myotubes were com-
pletely refractory to this cytokine with re-
spect to MyoD and MHC expression (Fig.
4A). Because other inflammatory cytokines
Fig. 2. MyoD is regulated by the p65 subunit of
NF-kB. (A) p65 suppresses MyoD expression.
10T1/2 fibroblasts were transfected with
MyoD, NF-kB, and IkBaSR expression plasmids
(23). Whole-cell lysates were prepared and
probed for MyoD and a-tubulin. (B) p65 sup-
presses MyoD mRNA expression. Transfections
were repeated in 100-mm culture dishes with
0.5 mg of vector or of MyoD expression plas-
mid, with or without 1.0 mg of p65 expression
plasmid. Cells were either kept in GM or differ-
entiated in DM, and at indicated times after
transfection, RNA was prepared and probed for
MyoD and GAPDH mRNA expression.
Fig. 3. Identification of the
MyoD sequences regulated by
p65-dependent transcription.
(A) p65 inhibits MyoD in a re-
gion encompassing nucleotides
539 through 914. The MyoD
cDNA was removed from plas-
mid pEMC11s, containing a long
terminal repeat element, and li-
gated into pCDNA3 (Invitrogen),
generating the plasmid pCMV-
MyoD. 59 and 39 deletions were
made in MyoD sequences (16).
Numerical values present in the
names of each plasmid denote
the location of the deletions
generated with respect to the 59
and 39 ends of the MyoD cDNA.
Wild-type MyoD (lanes 1 and 2) or deletion plasmids (lanes 3 through
10), each at 0.5 mg, were individually transfected in 10T1/2 fibroblasts
with or without a p65 expression plasmid (1.0 mg). RNA was extracted 24
hours after transfection, and MyoD was probed. Numerical values listed
with arrows indicate the predicted sizes of exogenously expressed MyoD
mRNA products. (B) p65 inhibits GAPDH expression containing MyoD
sequences. Nucleotides 313 through 914 from MyoD were ligated into
pCMVGAPDH, generating the plasmid pCMVGAPDH-MyoD. Transfec-
tions and RNA analysis were repeated as described in (A). The arrow
indicates endogenous GAPDH expression in 10T1/2 fibroblasts. (C) MyoD
regulation requires p65-dependent transcription. The upper portion
shows transfections performed in 10T1/2 fibroblasts with a MyoD-
responsive reporter (4RTK-Luc, containing four E-box sites fused to a
minimal thymidine kinase promoter), the pCMV-MyoD expression plas-
mid, and epitope-tagged p65 expression plasmids containing either
wild-type [Fp65(551)] or COOH-terminal deletions in the transactivation
domain. Cell extracts were prepared with M-Per Extraction Buffer (Pierce)
and tested in luciferase assays. The lower portion shows cell extracts
from transfections that were probed with an antibody to FLAG (M2,
Sigma) to verify the presence of equal p65 expression.
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such as interleukin-1b (IL-1b), IL-6, and
IFN-g also induce cachexia in animal models
(19), we investigated the possibility that one
of these cytokines in combination with TNF
could affect skeletal muscle cellular function.
Treatments with IL-1b or IL-6 alone or in
combination with TNF had no effect on skel-
etal muscle–specific gene expression (Fig.
4A) (15). In addition, IFN-g treatment alone
had no effect (15). However, differentiated
myotubes treated with TNF plus IFN-g
exhibited significant reductions in both
MyoD and MHC protein expression (Fig.
4A). Consistent with these results, immu-
nostaining analysis displayed dramatic di-
minishment of MHC after treatment with
TNF plus IFN-g (Fig. 4C) (16 ), which
correlated with the inability of myofibers to
maintain their contractile activities in cul-
ture (15). Apoptosis was observed in cul-
tures treated with TNF plus IFN-g, but only
in those myocytes unable to complete their
differentiation program (16 ), indicating
that the loss of muscle cell structure was
not a result of cell death. Thus, IFN-g and
TNF together regulate myotube degenera-
tion. When C2C12 myotubes devoid of NF-
kB activity were treated with TNF plus
IFN-g, they maintained both MyoD and
MHC expression (Fig. 4, B and C), indicat-
ing that repression of MyoD and impair-
ment of skeletal muscle function are NF-
kB– dependent processes.
To test whether TNF and IFN-g regulate
MyoD expression in vivo, we injected cyto-
kines directly into mouse skeletal muscle.
MyoD mRNA levels were substantially re-
duced after injection of the cytokines (Fig.
4D). A mixture of tumor-forming Chinese
hamster ovary (CHO) cells expressing TNF
(12) and IFN-g (20) was also injected into the
skeletal muscle of nude mice to more accu-
rately mimic a cachetic state. Again, these
cytokines caused a pronounced decline in
MyoD mRNA levels but had no effect on
GAPDH mRNA (Fig. 4D). These results sug-
gest that MyoD is an in vivo target of cyto-
kine signaling.
In adult skeletal muscle, MyoD is ex-
pressed at relatively low levels (21, 22).
However, in response to injury, MyoD ex-
pression is induced from satellite cells, and
genetic evidence clearly demonstrates that
MyoD is required for these cells to proliferate
and to reinitiate SMD necessary for the repair
process (4, 21). Our data demonstrate that
TNF, along with a second proinflammatory
cytokine, IFN-g, functions through NF-kB to
suppress MyoD synthesis by repressing the
accumulation of MyoD mRNA. With respect
to an injury model such as cachexia, we
propose that the cytokines TNF and IFN-g
are likely to affect skeletal muscle regulation
at two phases: first, when TNF alone would
be sufficient to suppress MyoD expression,
thereby inhibiting the formation of new myo-
fibers; and second, when combined signaling
between TNF and IFN-g would be required
to inhibit MyoD and cause the degeneration
of newly formed myotubes. The combined
cytokine effects, working through NF-kB,
would lead to the inability to repair damaged
skeletal muscle, thereby contributing to the
overall wasting process associated with ca-
chexia. Thus, direct inhibition of NF-kB may
prove beneficial in reducing the muscle wast-
ing associated with cachexia in cancer pa-
tients as well as with other disorders.
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Increase of Maximum Life-Span
in Sweden, 1861–1999
J. R. Wilmoth,1* L. J. Deegan,1 H. Lundström,2 S. Horiuchi3
A fundamental question in aging research is whether humans and other species
possess an immutable life-span limit. We examined the maximum age at death
in Sweden, which rose from about 101 years during the 1860s to about 108
years during the 1990s. The pace of increase was 0.44 years per decade before
1969 but accelerated to 1.11 years per decade after that date. More than 70
percent of the rise in the maximum age at death from 1861 to 1999 is
attributable to reductions in death rates above age 70. The rest are due to
increased numbers of survivors to old age (both larger birth cohorts and
increased survivorship from infancy to age 70). The more rapid rise in the
maximum age since 1969 is due to the faster pace of old-age mortality decline
during recent decades.
The world record of human life-span seems
to be moving upward over time, as suggested
by the death in 1997 of Jeanne Calment at the
documented age of 122.45 years (1). Howev-
er, such events are a poor measure of the
trend in achieved human life-span, which can
be studied more effectively using data for
well-defined populations. National demo-
graphic statistics suggest that the maximum
age at death has been rising steadily in indus-
trialized countries for more than 100 years
(2).
Two important questions arise from this
observation. First, has this upward trend been
steady over time, or has it changed pace in
recent years? Perhaps the increase has accel-
erated due to an intensification of efforts to
promote the health of the elderly and to pre-
vent or even cure ailments such as coronary
heart disease, stroke, and cancer. Or perhaps
the trend has decelerated because maximum
ages now observed for humans are approach-
ing a (hypothetical) biological limit. Second,
what accounts for the increase in the maxi-
mum age at death? There are two competing
explanations. One is that it is due merely to
the larger size of contemporary populations,
which increases the probability that at least
one individual will survive to an extreme old
age. Another possibility is that the increase
reflects improvements in an individual’s
probability of survival, especially at older
ages.
We have investigated these questions us-
ing Swedish national demographic data from
1861 to 1999, which are the longest available
series of reliable information on the upper
limits of achieved human life-span. Recorded
maximum ages at death for men and women
in Sweden centered around 101 years during
the 1860s and around 108 years during the
1990s (Fig. 1). A statistical analysis indicates
that the increase in the maximum age at death
accelerated markedly around 1969, rising at a
rate of 0.44 years per decade from 1861 to
1969 and 1.11 years per decade from 1969 to
1999. In both time periods, the maximum age
at death was on average about 1.7 years lower
for men than for women, although time
trends for both sexes are similar (3).
Apparent trends in the maximum age at
death can be distorted by changes in data
quality. Inaccurately reported ages of very
old persons and decedents have been com-
mon in official statistics for many countries
(2, 4). An improvement in data quality (i.e.,
fewer exaggerated reports of extreme old
age) may lead to a decrease over time in the
maximum reported age at death. Thus, a typ-
ical pattern is that the maximum age may
decline for several years as data quality im-
proves and then begin to increase. Only the
latter increase, not the earlier decrease, re-
flects a true trend. Mortality data since 1861
in Sweden show none of the typical signs of
age misreporting that are common elsewhere
(2). Mortality histories for the countries of
Western Europe and North America are
largely similar to the Swedish experience, but
no other country’s data offer the possibility
for reliable trend analysis in extreme old age
over such a long period. For this reason, only
Swedish data are used here, although the
results should apply broadly to the popula-
tions of other highly industrialized countries.
We analyzed the effect of changes in de-
mographic factors (birth counts and age-spe-
cific mortality rates) on the trend of the max-
imum age at death with the use of a model
that treats the observed maximum age as a
random variable with a theoretical probability
distribution. This distribution is determined
both by the underlying distribution of ages at
death for individuals and by the initial size of
a birth cohort (5). For this analysis, data on
the maximum age at death were reorganized
by year of birth (cohort) rather than by year
of death (period) (Fig. 2). These two trends
are similar and contain many of the same data
points. However, some points appear in one
series but not the other, because a death that
qualifies as the oldest for a birth cohort may
or may not be the oldest in the year of death,
and vice versa.
Our analysis of the cohort trend in the
maximum age at death relies on a reconstruc-
tion of Swedish mortality by year of birth
back to 1751. The life tables and the meth-
odology used to produce them are available
on our Web site (6). Although there may be
some question about the quality of period life
tables from late 18th-century Sweden (espe-
cially at older ages), life tables for cohorts
born in this era are more reliable because the
quality of the statistical system improved
over their lifetime. By the time such cohorts
attained age 100 or 110, where problems of
data quality are most severe, the Swedish
statistical system was extremely accurate (7).
In order to determine probability distribu-
tions of the maximum age at death, a se-
quence of age-specific death rates for each
cohort is needed. Death rates below age 80
were computed directly from national mor-
tality statistics, reorganized in a cohort for-
mat (8). Death rates above age 80 were esti-
mated by fitting a logistic function to ob-
served death rates and then extrapolating this
function to very high ages (9). It was neces-
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